1.
TPC3: COST OF AML TREATMENT IN BELGIUM: RESULTS OF A RANDOMIZED TRIAL WITH AND WITHOUT FILGRASTIM USE
2.
3.
4.
Plerixafor prescription modalities in autologous haematopoietic stem cell mobilization in Belgium
Myelofibrosis patients in Belgium : disease characteristics